MCID: CRV031
MIFTS: 53

Cervical Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Cervical Adenocarcinoma

MalaCards integrated aliases for Cervical Adenocarcinoma:

Name: Cervical Adenocarcinoma 12 60 56 15 17 74
Adenocarcinoma of the Uterine Cervix 12
Adenocarcinoma of the Cervix Uteri 60
Adenocarcinoma Cervix Uteri 12
Adenocarcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3702
NCIt 51 C4029
ICD10 via Orphanet 35 C53.0 C53.1 C53.8
UMLS via Orphanet 75 C0279672
Orphanet 60 ORPHA213772
UMLS 74 C0279672

Summaries for Cervical Adenocarcinoma

Disease Ontology : 12 A cervix carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Cervical Adenocarcinoma, also known as adenocarcinoma of the uterine cervix, is related to glassy cell carcinoma of the cervix and adenocarcinoma. An important gene associated with Cervical Adenocarcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Gastric cancer. The drugs Cisplatin and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Cervical Adenocarcinoma

Diseases in the Cervical Adenocarcinoma family:

Early Invasive Cervical Adenocarcinoma

Diseases related to Cervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 274)
# Related Disease Score Top Affiliating Genes
1 glassy cell carcinoma of the cervix 32.8 ERBB2 ESR1
2 adenocarcinoma 31.4 CDKN2A ERBB2 PTGS2 TP53
3 adenocarcinoma in situ 31.0 CDKN2A CDX2 KRT20 KRT7
4 mucinous adenocarcinoma 31.0 CDKN2A CDX2 KRT20 KRT7
5 papillary serous adenocarcinoma 30.8 KRT20 KRT7 TP53
6 signet ring cell adenocarcinoma 30.6 CDX2 KRT20 KRT7
7 appendix adenocarcinoma 30.4 CDX2 KRT20 KRT7
8 endocervical adenocarcinoma 30.4 CDKN2A CDX2 KRT20 KRT7 TP53
9 squamous cell carcinoma 30.2 CDKN2A ERBB2 PTGS2 TP53
10 papillary transitional carcinoma 29.9 KRT20 KRT7
11 cervical squamous cell carcinoma 29.8 CDKN2A RASSF1 TP53
12 suppressor of tumorigenicity 3 29.8 CDKN1A CDKN2A TP53
13 papillary adenocarcinoma 29.8 ERBB2 KRT7 TP53
14 small cell carcinoma 29.7 CDKN2A KRT20 KRT7 TP53
15 ovarian cancer 1 29.5 ERBB2 KRT7 TP53
16 vulval paget's disease 29.5 CDKN2A ERBB2 KRT20 KRT7
17 transitional cell carcinoma 29.4 CDKN2A ERBB2 KRT20 KRT7 PTGS2 TP53
18 papilloma 29.4 CDKN1A CDKN2A KRT20 KRT7 TP53
19 gastric cancer 29.1 CDKN1A CDKN2A CDX2 ERBB2 KRT20 PTGS2
20 lung cancer 28.4 CDKN1A CDKN2A ERBB2 KRT20 KRT7 PTGS2
21 endometrial cancer 28.3 CDKN1A CDKN2A EBAG9 ERBB2 ESR1 KRT7
22 early invasive cervical adenocarcinoma 12.5
23 cervical mucinous adenocarcinoma 11.1
24 cervical clear cell adenocarcinoma 11.1
25 wolffian duct adenocarcinoma 11.1
26 cervical serous adenocarcinoma 11.1
27 cervical endometrioid adenocarcinoma 11.1
28 balanitis xerotica obliterans 10.5 CDKN2A PTGS2
29 bowenoid papulosis 10.5 CDKN2A PTGS2
30 bile reflux 10.5 CDX2 PTGS2
31 anal canal carcinoma 10.5 CDKN2A KRT7
32 duodenum adenocarcinoma 10.5 CDX2 KRT7
33 anal canal adenocarcinoma 10.5 CDX2 KRT7
34 epithelial predominant wilms' tumor 10.5 CDX2 KRT7
35 large intestine adenocarcinoma 10.5 KRT20 KRT7
36 thyroid lymphoma 10.5 CDKN2A TP53
37 bladder lymphoma 10.5 KRT20 KRT7
38 megaesophagus 10.5 CDKN2A TP53
39 vulva squamous cell carcinoma 10.5 CDKN2A TP53
40 scrotal carcinoma 10.5 CDKN2A TP53
41 linitis plastica 10.5 KRT20 KRT7
42 bladder squamous cell carcinoma 10.5 CDKN2A TP53
43 bile duct cystadenocarcinoma 10.5 KRT20 KRT7
44 medulloepithelioma 10.5 KRT20 KRT7
45 adenoid squamous cell carcinoma 10.5 KRT20 KRT7
46 keratinizing squamous cell carcinoma 10.5 CDKN2A TP53
47 anal squamous cell carcinoma 10.5 CDKN2A TP53
48 gastric adenosquamous carcinoma 10.5 CDKN2A TP53
49 eyelid carcinoma 10.5 KRT20 KRT7
50 bartholin's gland disease 10.5 CDKN2A TP53

Graphical network of the top 20 diseases related to Cervical Adenocarcinoma:



Diseases related to Cervical Adenocarcinoma

Symptoms & Phenotypes for Cervical Adenocarcinoma

GenomeRNAi Phenotypes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CDKN1A CDKN2A EBAG9 LAMC2 MCM5 TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 CDKN1A CDKN2A EBAG9 LAMC2 MCM5 TP53

MGI Mouse Phenotypes related to Cervical Adenocarcinoma:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 CDKN1A CDKN2A CDX2 ERBB2 ESR1 KRT7
2 digestive/alimentary MP:0005381 10.16 CDKN1A CDKN2A CDX2 ERBB2 ESR1 LAMC2
3 homeostasis/metabolism MP:0005376 10.16 CDKN1A CDKN2A CDX2 ERBB2 ESR1 KRT7
4 cardiovascular system MP:0005385 10.14 CDKN1A CDKN2A CDX2 ERBB2 ESR1 PTGS2
5 endocrine/exocrine gland MP:0005379 10.08 CDKN1A CDKN2A CDX2 ERBB2 ESR1 PTGS2
6 embryo MP:0005380 10.04 CDKN1A CDKN2A CDX2 ERBB2 ESR1 PTGS2
7 integument MP:0010771 9.98 CDKN1A CDKN2A ERBB2 ESR1 LAMC2 PTGS2
8 neoplasm MP:0002006 9.92 CDKN1A CDKN2A CDX2 ERBB2 ESR1 PTGS2
9 limbs/digits/tail MP:0005371 9.88 CDKN1A CDX2 ERBB2 ESR1 LAMC2 TP53
10 liver/biliary system MP:0005370 9.85 CDKN1A CDKN2A ESR1 PTGS2 RASSF1 TP53
11 normal MP:0002873 9.8 CDX2 ERBB2 ESR1 PTGS2 RASSF1 TP53
12 renal/urinary system MP:0005367 9.63 CDKN1A ESR1 KRT7 LAMC2 PTGS2 TP53
13 respiratory system MP:0005388 9.5 CDKN1A CDKN2A ERBB2 ESR1 LAMC2 PTGS2
14 skeleton MP:0005390 9.23 CDKN1A CDKN2A CDX2 ERBB2 ESR1 LAMC2

Drugs & Therapeutics for Cervical Adenocarcinoma

Drugs for Cervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
2 Vaccines Phase 4,Phase 3,Phase 2
3 Epoetin alfa Phase 4,Phase 3 113427-24-0
4 Hematinics Phase 4,Phase 3
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
7
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
8
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
9
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
10
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
11
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
12
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
13
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
14
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
15
Ifosfamide Approved Phase 3 3778-73-2 3690
16
Vinblastine Approved Phase 3 865-21-4 13342 241903
17
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
19
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
20 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
21 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
22 Antimitotic Agents Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Antiviral Agents Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
26 Immunologic Factors Phase 3,Phase 2,Phase 1
27 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
28 Immunoglobulin G Phase 3,Phase 2
29 Angiogenesis Modulating Agents Phase 3,Phase 2
30 Angiogenesis Inhibitors Phase 3,Phase 2
31 Immunoglobulins Phase 3,Phase 2,Phase 1
32 Antibodies Phase 3,Phase 2,Phase 1
33 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
34 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
35 Endothelial Growth Factors Phase 3,Phase 2
36 Mitogens Phase 3,Phase 2
37 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
38 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
39 Antimetabolites Phase 3,Phase 2,Phase 1
40 Vitamin B Complex Phase 3,Phase 2
41 Mitomycins Phase 3
42 Antineoplastic Agents, Alkylating Phase 3,Phase 2
43 Anti-Bacterial Agents Phase 3,Phase 2
44
Isophosphamide mustard Phase 3 0
45 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
46 Alkylating Agents Phase 3,Phase 2
47 Antibiotics, Antitubercular Phase 3,Phase 2
48 Folate Phase 3,Phase 2
49 Vitamin B9 Phase 3,Phase 2
50 Dermatologic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
2 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
3 Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) Completed NCT00834106 Phase 3
4 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
5 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
6 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
8 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
9 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
10 Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
11 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
12 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) Active, not recruiting NCT03493542 Phase 3
13 Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer Active, not recruiting NCT02853604 Phase 3 ADXS11-001;Placebo
14 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
15 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
16 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
17 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
18 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
19 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
20 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
21 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
22 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
23 Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application Completed NCT01639625 Phase 2 CIGB300
24 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
25 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2 Capecitabine
26 ADXS11-001 High Dose HPV+ Cervical Cancer Completed NCT02164461 Phase 1, Phase 2
27 Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Completed NCT02562729 Phase 2
28 Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL Completed NCT01957878 Phase 2
29 Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01267253 Phase 2 Brivanib Alaninate
30 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
31 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
32 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
33 Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer Completed NCT00002562 Phase 2 paclitaxel
34 Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005999 Phase 2 arsenic trioxide
35 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
36 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
37 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
38 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
39 Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix Completed NCT00003065 Phase 2 paclitaxel;topotecan hydrochloride
40 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
41 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
42 FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Completed NCT00559377 Phase 2
43 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
44 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed NCT00369122 Phase 2 Cisplatin
45 Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery Completed NCT01229930 Phase 2 carboplatin;cediranib maleate;paclitaxel
46 Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer Completed NCT00807079 Phase 1, Phase 2 carboplatin;topotecan hydrochloride
47 Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer Completed NCT00957411 Phase 2 cisplatin
48 Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer Completed NCT00012012 Phase 1, Phase 2 Amifostine trihydrate;Cisplatin
49 Radiation Therapy in Treating Patients With Cervical Cancer Completed NCT00278304 Phase 2
50 Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00101192 Phase 2 cisplatin

Search NIH Clinical Center for Cervical Adenocarcinoma

Genetic Tests for Cervical Adenocarcinoma

Anatomical Context for Cervical Adenocarcinoma

MalaCards organs/tissues related to Cervical Adenocarcinoma:

42
Cervix, Lymph Node, Testes, Liver, Ovary, Endothelial, Colon

Publications for Cervical Adenocarcinoma

Articles related to Cervical Adenocarcinoma:

(show top 50) (show all 551)
# Title Authors Year
1
≤ Cyclin D1 protein affecting global women's health by regulating HPV mediated adenocarcinoma of the uterine cervix. ( 30903019 )
2019
2
Micropapillary Cervical Adenocarcinoma: A Clinicopathologic Study of 44 Cases. ( 30864975 )
2019
3
Metastatic cervical adenocarcinoma to the breast: A case report and literature review. ( 30815528 )
2019
4
Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables. ( 30819439 )
2019
5
Cytological diagnosis of a rare case of alpha-fetoprotein producing gastric-type adenocarcinoma of the uterine cervix. ( 30861248 )
2019
6
Clinical and MRI Characteristics of Uterine Cervical Adenocarcinoma: Its Variants and Mimics. ( 30799567 )
2019
7
Clinicopathological characteristics of patients with mucinous adenocarcinoma of the uterine cervix: a retrospective study of 21 cases. ( 30807852 )
2019
8
Sellar Metastasis of Cervical Adenocarcinoma. ( 30733881 )
2019
9
Perivascular epithelioid cell tumour and mesonephric adenocarcinoma of the uterine cervix: an unknown co-existence. ( 30697432 )
2019
10
Trefoil factor family 2 protein: a potential immunohistochemical marker for aiding diagnosis of lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix. ( 30324235 )
2019
11
Cervical Adenocarcinoma: A Comparison of the Reproducibility of the World Health Organization 2003 and 2014 Classifications. ( 29474242 )
2018
12
Uterine cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia: Radiologic-pathologic correlation. ( 29144012 )
2018
13
Morphologic Features of Gastric-type Cervical Adenocarcinoma in Small Surgical and Cytology Specimens. ( 29750702 )
2018
14
Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001). ( 29341491 )
2018
15
miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-I^RI signaling pathway. ( 29531222 )
2018
16
Ovarian conservation is associated with better survival in young patients with T1N0M0 cervical adenocarcinoma: a population-based study. ( 29362924 )
2018
17
Postoperative clinicopathological factors affecting cervical adenocarcinoma: Stages I-IIB. ( 29480826 )
2018
18
Concomitant endometrial and cervical adenocarcinoma: A case report and literature review. ( 29505548 )
2018
19
MiR-362-3p functions as a tumor suppressor through targeting MCM5 in cervical adenocarcinoma. ( 29871972 )
2018
20
The safety of fertility preservation for microinvasive cervical adenocarcinoma: a meta-analysis and trial sequential analysis. ( 29876746 )
2018
21
Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients. ( 30538552 )
2018
22
Molecular prognostic factors in early-stage cervical adenocarcinoma. ( 30509055 )
2018
23
Effect of tibolone on the survival of early stage cervical adenocarcinoma patients. ( 30254994 )
2018
24
RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern? ( 30284744 )
2018
25
Estrogen/GPR30 Signaling Contributes to the Malignant Potentials of ER-Negative Cervical Adenocarcinoma via Regulation of Claudin-1 Expression. ( 30227306 )
2018
26
Bioinformatics analysis of methylation in cervical adenocarcinoma in Xinjiang, China. ( 30170437 )
2018
27
Euphornin reduces proliferation of human cervical adenocarcinoma HeLa cells through induction of apoptosis and G2/M cell cycle arrest. ( 30100745 )
2018
28
Survival benefits with the addition of adjuvant hysterectomy to radiochemotherapy for treatment of stage I-II adenocarcinoma of the uterine cervix. ( 30114328 )
2018
29
Disease-free survival after robotic-assisted laparoscopic total pelvic exenteration for recurrent cervical adenocarcinoma: A case report. ( 30045297 )
2018
30
Is the ovarian preservation safe in young women with stages IB-IIA villoglandular adenocarcinoma of the uterine cervix? ( 29770624 )
2018
31
Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix - An Italian Multicenter Retrospective Study. ( 29848719 )
2018
32
Gastric-Type Adenocarcinoma of the Uterine Cervix: Magnetic Resonance Imaging Features, Clinical Outcomes, and Prognostic Factors. ( 29683881 )
2018
33
Surgical treatment and outcome of early invasive adenocarcinoma of the uterine cervix (FIGO stage IA1). ( 28429457 )
2018
34
The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix. ( 29404709 )
2018
35
Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma. ( 28331901 )
2017
36
Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. ( 28102052 )
2017
37
Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia. ( 28720447 )
2017
38
Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells. ( 29067110 )
2017
39
Early-stage node negative cervical adenocarcinoma and squamous cell carcinoma show similar survival outcomes after hysterectomy: a population-based study. ( 29027399 )
2017
40
Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins. ( 28181670 )
2017
41
Tumor-associated CD204<sup>+</sup>M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma. ( 29274107 )
2017
42
Cervical Adenocarcinoma: Diagnosis of Human Papillomavirus-Positive and Human Papillomavirus-Negative Tumors. ( 28644686 )
2017
43
Assessment of anti-cancerous potential of 6-gingerol (Tongling White Ginger) and its synergy with drugs on human cervical adenocarcinoma cells. ( 28249781 )
2017
44
Methods for Measuring and Staging a Uterine Cervical Adenocarcinoma Showing Intracystic Papillary Growth: A Case Report. ( 28700431 )
2017
45
Should ovaries be removed or not in early-stage cervical adenocarcinoma: a multicenter retrospective study of 105 patients. ( 28631536 )
2017
46
Immunohistochemical Expression of the Tumor Suppressor Protein p16INK4a in Cervical Adenocarcinoma. ( 28245508 )
2017
47
Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. ( 28851799 )
2017
48
Metastatic cervical adenocarcinoma to the orbital subperiosteal space. ( 28457305 )
2017
49
Cervical Adenocarcinoma Has a Poorer Prognosis and a Higher Propensity for Distant Recurrence Than Squamous Cell Carcinoma. ( 28604449 )
2017
50
Role of positive peritoneal cytology in FIGO stage IB to IIB cervical adenocarcinoma. ( 28186628 )
2017

Variations for Cervical Adenocarcinoma

Expression for Cervical Adenocarcinoma

Search GEO for disease gene expression data for Cervical Adenocarcinoma.

Pathways for Cervical Adenocarcinoma

Pathways related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 CDKN1A ERBB2 LAMC2 PTGS2 TP53
2
Show member pathways
12.47 CDKN1A CDKN2A CDX2 ERBB2 ESR1 TP53
3
Show member pathways
12.44 CDKN1A CDKN2A ERBB2 ESR1 RASSF1 TP53
4
Show member pathways
12.4 CDKN1A CDKN2A MCM5 TP53
5 12.21 CDKN1A CDKN2A MCM5 TP53
6 12.14 CDKN1A ERBB2 ESR1 TP53
7 12.11 CDKN1A CDKN2A ERBB2 PTGS2 RASSF1 TP53
8 11.95 CDKN1A CDKN2A ERBB2 ESR1 LAMC2 PTGS2
9 11.84 CDKN1A PTGS2 TP53
10 11.82 CDKN1A CDKN2A TP53
11 11.82 CDKN1A CDKN2A ERBB2 TP53
12 11.78 CDKN1A CDKN2A TP53
13
Show member pathways
11.7 CDKN1A ERBB2 ESR1
14 11.67 CDKN1A LAMC2 PTGS2 TP53
15 11.42 CDKN1A CDKN2A ERBB2 TP53
16 11.41 CDKN1A PTGS2 TP53
17 11.39 CDKN1A CDKN2A TP53
18 11.35 CDKN1A ESR1 PTGS2
19 11.22 CDKN1A CDKN2A ERBB2 RASSF1 TP53
20 11.2 ESR1 PTGS2 TP53
21
Show member pathways
10.95 CDKN1A CDKN2A TP53
22 10.65 CDKN1A TP53

GO Terms for Cervical Adenocarcinoma

Cellular components related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.02 CDKN1A CDX2 ESR1 PTGS2 TP53

Biological processes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.85 CDKN2A EBAG9 KRT20 TP53 VIL1
2 cell cycle GO:0007049 9.83 CDKN1A CDKN2A MCM5 RASSF1 TP53
3 negative regulation of cell growth GO:0030308 9.67 CDKN1A CDKN2A TP53
4 G1/S transition of mitotic cell cycle GO:0000082 9.58 CDKN1A CDKN2A MCM5
5 negative regulation of phosphorylation GO:0042326 9.48 CDKN1A CDKN2A
6 cell cycle arrest GO:0007050 9.46 CDKN1A CDKN2A RASSF1 TP53
7 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.37 ESR1 TP53
8 negative regulation of immature T cell proliferation in thymus GO:0033088 9.32 CDKN2A ERBB2
9 signal transduction by p53 class mediator GO:0072331 9.26 CDKN1A TP53
10 Ras protein signal transduction GO:0007265 9.26 CDKN1A CDKN2A RASSF1 TP53
11 replicative senescence GO:0090399 8.8 CDKN1A CDKN2A TP53

Molecular functions related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN1A CDKN2A

Sources for Cervical Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....